BGMS

#4898
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-2.27%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q1 FY2014

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on March 17, 2014. The filing discloses corporate governance updates regarding executive employment agreements and a dividend declaration for preferred stockholders.

Key Financial Metrics and Compensation

  • Executive Compensation:
    • Spiro Rombotis (CEO): Base salary increased to $530,553.
    • Paul McBarron (EVP-Finance, CFO, COO): Base salary increased to £208,859.
  • Dividend Declaration: A quarterly cash dividend of $0.15 per share was declared on the Company's 6% Convertible Exchangeable Preferred Stock.
  • Liquidity and Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or total debt.

Material Changes

  • Employment Terms: Employment agreements for the CEO and CFO were renewed effective January 1, 2014, extending the term through January 1, 2017. Base salaries for both officers were increased.
  • Dividend Policy: The Board declared a dividend for the current quarter but explicitly stated there is no assurance that future quarterly dividends will be declared.

Outlook, Risks, and Management Commentary

Management noted that the Board considered financial analysis and surplus determination before declaring the dividend. The filing highlights the risk that future dividends are not guaranteed. The full employment agreements are scheduled to be filed as exhibits to the Annual Report on Form 10-K for the year ended December 31, 2013.

Investor Verification Checklist

  • Verify the exact terms of the renewed employment agreements in the upcoming Form 10-K filing.
  • Confirm the record date (April 18, 2014) and payment date (May 1, 2014) for the $0.15 preferred stock dividend.
  • Review the company's cash position in the most recent 10-K to assess the ability to fund the dividend and increased executive salaries.
  • Note the discrepancy between the requested company name (Bio Green Med Solution) and the actual registrant (Cyclacel Pharmaceuticals).